Skip to main content
VP

VELOXIS PHARMACEUTICALS A/S

aktiv
CVR 26527767AktieselskabGdanskgade 18, 2150 NordhavnForskning og eksperimentel udvikling inden for naturvidenskab og teknik
Latest accounts
2026
Statement scope
Consolidated
Verified
22 Nov 2026
Sources
5

What changed?

Source-backed changes, not an assessment.

2026
Source note

Source access required

CVR360 has not loaded official Danish source data for this company yet. No AI or financial conclusion is generated without source-backed facts.

1 source

Key figures

Latest period: 2026

Revenue

Data quality concern

—

Data quality concern

Operating profit

DKK -1.2m

Latest period

Source details

Source: dk-regnskabsdata-live-26527767-1795321228371

Document: dk-regnskabsdata-26527767-AaE5dsy5ntWaBrQWnPhA-1

XBRL: ifrs-full:ProfitLossFromOperatingActivities

Period: 01 Apr 2025 - 31 Mar 2026

Technical details

Context: ctx-4

Unit: dkk

Net result

DKK -1.6m

Latest period

Source details

Source: dk-regnskabsdata-live-26527767-1795321228371

Document: dk-regnskabsdata-26527767-AaE5dsy5ntWaBrQWnPhA-1

XBRL: ifrs-full:ProfitLoss

Period: 01 Apr 2025 - 31 Mar 2026

Technical details

Context: ctx-4

Unit: dkk

Equity

DKK 611.6m

Equity ratio: 99.8%

Source details

Source: dk-regnskabsdata-live-26527767-1795321228371

Document: dk-regnskabsdata-26527767-AaE5dsy5ntWaBrQWnPhA-1

XBRL: ifrs-full:Equity

Period: 01 Apr 2025 - 31 Mar 2026

Technical details

Context: ctx-6

Unit: dkk

Development

Reported values. Missing periods appear as gaps.

Open full financials
RevenueNet result
Tabular view of development
YearRevenueNet result
2022——
2023—DKK -103k
2024—DKK -13.3m
2025—DKK -644k
2026—DKK -1.6m